Headlands Research

09/03/2026

Treatment-resistant depression (TRD) continues to challenge patients and clinicians, highlighting the need for faster-acting, more durable, and more personalized treatment options.

In this blog, Pieter Strauss, MD, MBChB, FRCPC, Principal Investigator at Headlands Research - Okanagan Clinical Trials, explores emerging approaches to TRD, including biomarkers and AI-enabled treatment personalization, glutamate modulators, and psychedelics.

Read the blog to learn how these innovations could reshape the future of depression treatment and clinical research: https://headlandsresearch.com/blogs/rethinking-treatment-resistant-depression-innovative-therapies-for-rapid-relief-and-durable-outcomes/

09/01/2026

The Headlands Research team is looking forward to attending Partnerships with Sites on September 14th and DPHARM 2026 on September 15 - 16, where industry leaders will explore new approaches to modernizing clinical trials, reducing operational burden, and accelerating research.

If you'll be at DPHARM, connect with Lauren Chazal, Chief Business Development Officer, or Liz Sonsalla, Director, Strategic Partnerships. We'd love to discuss how our leading site network helps sponsors and CROs deliver high-quality research through experienced sites, broad therapeutic expertise, and access to diverse patient populations.

https://headlandsresearch.com/events/dpharm-2026/

08/27/2026

Alzheimer’s research continues to move toward earlier detection, and a new FDA-approved blood test could make that process more accessible for patients. Dr. Linda Pao, Medical Director and Principal Investigator at Headlands Research JEM, recently spoke with WPBF News about the potential impact of the new test, including its convenience and its ability to help primary care physicians identify patients who may benefit from additional evaluation.

Dr. Pao explains that amyloid changes associated with Alzheimer’s can begin years before symptoms appear. Earlier detection could play an important role as new approaches to prevention and treatment continue to emerge.

Read the full article to hear more about what this development could mean for the future of Alzheimer’s care and research: https://www.wpbf.com/article/florida-alzheimer-s-disease-blood-test-fda-medical/73524599

The FDA has approved a blood test developed by Roche to detect Alzheimer's disease in adults 55 and older experiencing cognitive loss, offering a less invasive diagnostic option.

08/25/2026

Bart Williams, MD, is a Principal Investigator at Headlands Research TMA-Wilmington, and a board-certified family physician with more than 20 years of experience in clinical research and patient care.

Throughout his career, Dr. Williams has led numerous Phase II and Phase III vaccine trials, including studies evaluating vaccines for COVID-19, RSV, and influenza. His research has contributed to the development of innovative vaccines that help protect communities and improve public health.

In addition to his research leadership, Dr. Williams has built lasting relationships with patients through his long-standing practice at Wrightsville Family Practice in Wilmington, North Carolina. His compassionate, community-centered approach to care continues to guide his work as he helps bring new therapies to patients through clinical research.

08/20/2026

What does it take to successfully execute a neurodegenerative disease clinical trial? From subjective cognitive assessments and biomarker collection to intensive safety monitoring and long-term participant retention, CNS trials demand specialized expertise at every stage.

In his latest blog, Dr. Scott Losk, Principal Investigator at Headlands Summit Research, explores how CNS-specialized site networks can help sponsors improve trial quality, accelerate enrollment, reduce operational risk, and generate stronger evidence for regulatory and payer review.

Read the full blog to learn why strategic site selection matters: https://headlandsresearch.com/blogs/how-site-networks-with-cns-expertise-drive-neurodegenerative-trial-success/

08/18/2026

A new phase II study found that an investigational quadrivalent measles, mumps, rubella, and varicella (MMRV) vaccine generated immune responses comparable to the licensed MMRV vaccine in children ages 4–6, with a similar safety profile. These findings support continued clinical development and the potential to expand vaccine availability for children worldwide.

We're proud to recognize Carmen Deseda, MD, Principal Investigator at Headlands CMR Center, as a co-author on this important publication. Congratulations to Dr. Deseda and all study collaborators for advancing pediatric vaccine research and helping strengthen disease prevention for future generations.

Learn more: https://headlandsresearch.com/news/immunogenicity-and-safety-of-an-investigational-quadrivalent-measles-mumps-rubella-and-varicella-vaccine/

08/13/2026

As our understanding of Alzheimer's disease evolves, so does the potential to diagnose earlier, intervene sooner, and improve outcomes for patients and families.

In this blog, Scott Losk, PhD, Principal Investigator at Headlands Summit Research, explores how advances in blood-based biomarkers, precision diagnostics, novel therapies, and more convenient treatment approaches are reshaping the future of neurological disease research.

Drawing on his experience leading 90 Alzheimer's disease clinical trials and contributing to the research behind every FDA-approved Alzheimer's therapy available today, Dr. Losk shares why the field is moving toward earlier detection, more personalized care, and greater hope for those affected by dementia.

Read the blog: https://headlandsresearch.com/blogs/clinical-research-in-dementias-progress-challenges-and-future-directions/

08/11/2026

Dr. Vanessa Sepulveda serves as a Principal Investigator at CMRC Headlands Research. Board-certified in Internal Medicine and Geriatrics, she combines decades of clinical care with academic leadership and extensive research experience in Alzheimer's disease and related cognitive disorders.

As a recognized leader in the field, Dr. Sepulveda has served on the Alzheimer's Association Scientific Program Committee and has presented her research at leading scientific meetings, including the Alzheimer's Association International Conference (AAIC). In 2015, the Journal of the American Geriatrics Society recognized "Un Café por el Alzheimer", the community education initiative she founded to raise awareness about Alzheimer's disease in Puerto Rico. Since then, the initiative has continued, year after year, to educate and accompany patients, caregivers, and the Puerto Rican community through accessible, evidence-based information and outreach efforts.

Her research has focused on Alzheimer's disease and related dementias in Hispanic and Latino populations, including studies on the gut microbiome's role in cognitive decline and the development of tools to support family caregivers. As a Principal Investigator at Headlands Research Puerto Rico, she is committed to expanding access to clinical trials that bring promising therapies to patients while advancing the science of Alzheimer's disease. Throughout her career, Dr. Sepulveda has remained committed to the belief that advancing Alzheimer's care requires both scientific discovery and continuous community education. We're proud to have her expertise strengthening our network of investigators.

08/05/2026

Headlands Research is expanding its presence in the Pacific Northwest with the opening of Headlands Research Western Washington, a new purpose-built clinical research site in Bellingham, WA!

Led by Matthew Bogoyas, DO, a board-certified psychiatrist and 2025 Fellow of the American Psychiatric Association, the site gives sponsors access to a large, underserved CNS research market with more than 615,000 people within a 50-mile radius. The new site strengthens our ability to support neuropsychiatric research while bringing clinical trial opportunities closer to participants in Western Washington.

Read the press release: https://headlandsresearch.com/news/headlands-research-expands-pacific-northwest-presence-with-new-clinical-research-site-in-bellingham-washington/

08/04/2026

Multidose vial presentations (MDV) are a well-established tool for vaccine access. They reduce per-dose cost, simplify logistics, and fit within the infrastructure of lower-resource settings.

Jon Finley, MD, Principal Investigator at Headlands Clinical Research Atlanta (CRA), is among the co-authors on a new phase 3 study published in eClinicalMedicine confirming that the RSVpreF vaccine fits that model. The MDV presentation matched the licensed single-dose vial on immunogenicity, with a comparable safety and tolerability profile. Research like this could help make RSV vaccination more accessible worldwide.

Read more: https://headlandsresearch.com/news/safety-and-immunogenicity-of-bivalent-rsvpref-vaccine/